While Japan has now granted its first emergency approval to Shionogi’s COVID-19 pill Xocova (ensitrelvir), the drug failed to win a unanimous vote by advisory panels, with skepticism lingering over its actual efficacy. To prep for the next emergency, which…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY First Committee Recommends Approval for New Gout, Hyperuricemia Treatment, Antihypertensive Tape Formulation
May 1, 2013
-
REGULATORY PMRJ Introduces “RS Expert Certification System”
April 30, 2013
-
BUSINESS Boehringer Filed NDA for Afatinib in Japan: Chairman
April 26, 2013
-
BUSINESS Edoxaban Will Be Key to Achieving Targets in Daiichi Sankyo’s New 5-Year Business Plan
April 26, 2013
-
ORGANIZATION Itsuro Yoshida of Towa Pharmaceutical Expected to Take Over as Next President of JGA
April 25, 2013
-
REGULATORY Bill to Amend PAL Will Be Submitted to Diet in May, as Instructed by PM Abe: Mr Akagawa of PFSB
April 25, 2013
-
ACADEMIA RA Treatment Guidelines to Reflect Patients’ Values and Economic Considerations as Well as Evidence
April 24, 2013
-
ACADEMIA New COPD Guidelines Recommend LAMA, LABA on Equal Footing
April 23, 2013
-
BUSINESS Pfizer-Mylan Pair’s Japan Generic Share at 2.8%, Aspire for Bigger Slice of Market
April 22, 2013
-
BUSINESS Tug-of-War over “Conflicts of Interest” (2): “Diovan Scandal” Brings Renewed Attention to COI
April 19, 2013
-
BUSINESS Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus
April 18, 2013
-
ORGANIZATION Tug-of-War over “Conflicts of Interest” (1): Drug Makers, Doctors Remain Divided
April 18, 2013
-
BUSINESS Teijin Pharma Hopes to Derive 50%-Plus of Sales from New Drugs by around 2016: Pres. Uno
April 17, 2013
-
REGULATORY Growing Concern Over Return to Brand Names for Generics with Advent of Generic Versions of Combination Drugs
April 16, 2013
-
REGULATORY Supreme Court Rejects Damage Claims in Iressa Suits; Govt, AZ Win 8-Year Battle
April 15, 2013
-
BUSINESS 11 Drug Makers to Increase, 11 to Decrease Hiring Next Year; Mid-Sized Companies Most Optimistic on Hiring
April 15, 2013
-
REGULATORY Generic Roadmap: CSIMC Bill Payer Rep Says New 60% Target Could “Decelerate” Shift
April 12, 2013
-
BUSINESS Eisai Announces Organizational Reforms; “We Won’t Allow Generics to Overwhelm AD Market”: President Naito
April 12, 2013
-
BUSINESS Shire Enters Japan Full Force, Six Products to Be Launched in Five Years
April 11, 2013
-
BUSINESS Amgen Plans New Product Debuts in Japan by 2016, Pins Hopes on Hyperlipidemia Drug
April 10, 2013
ページ
As the year 2022 draws to a close, what are managers thinking at the world’s leading pharmaceutical companies and medical device companies? We surveyed 86 managers at these companies to find out what’s on their minds.For many managers, a common…
A Japanese reimbursement policy panel on November 16 saw a continued scuffle between members representing healthcare providers and payers over…
Deloitte Tohmatsu Consulting proposed three drug pricing schemes designed to trigger the consolidation of generic makers on October 27, offering…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…